Literature DB >> 33680360

Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins.

Yuanhao Wang1, Dong Ji2, Chaoyu Lei1, Yingfei Chen1, Yuran Qiu1, Xinyi Li1, Mingyu Li1, Duan Ni1,3, Jun Pu4, Jian Zhang1,5, Qiang Fu6, Yaqin Liu5, Shaoyong Lu1,5.   

Abstract

Ras undergoes interconversion between the active GTP-bound state and the inactive GDP-bound state. This GTPase cycle, which controls the activities of Ras, is accelerated by Ras GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (SOS). Oncogenic Ras mutations could affect the GTPase cycle and impair Ras functions. Additionally, Src-induced K-Ras Y32/64 dual phosphorylation has been reported to disrupt GTPase cycle and hinder Ras downstream signaling. However, the underlying mechanisms remain unclear. To address this, we performed molecular dynamics simulations (~30 μs in total) on unphosphorylated and phosphorylated K-Ras4B in GTP- and GDP-bound states, and on their complexes with GTPase cycle regulators (GAP and SOS) and the effector protein Raf. We found that K-Ras4B dual phosphorylation mainly alters the conformation at the nucleotide binding site and creates disorder at the catalytic site, resulting in the enlargement of GDP binding pocket and the retard of Ras-GTP intrinsic hydrolysis. We observed phosphorylation-induced shift in the distribution of Ras-GTP inactive-active sub-states and recognized potential druggable pockets in the phosphorylated Ras-GTP. Moreover, decreased catalytic competence or signal delivery abilities due to reduced binding affinities and/or distorted catalytic conformations of GAP, SOS and Raf were observed. In addition, the allosteric pathway from Ras/Raf interface to the distal Raf L4 loop was compromised by Ras phosphorylation. These results reveal the mechanisms by which phosphorylation influences the intrinsic or GAP/SOS catalyzed transformations between GTP- and GDP-bound states of Ras and its signal transduction to Raf. Our findings project Ras phosphorylation as a target for cancer drug discovery.
© 2021 The Author(s).

Entities:  

Keywords:  Drug discovery; K-Ras; Molecular dynamics simulations; Phosphorylation; Protein-protein interactions

Year:  2021        PMID: 33680360      PMCID: PMC7902900          DOI: 10.1016/j.csbj.2021.01.044

Source DB:  PubMed          Journal:  Comput Struct Biotechnol J        ISSN: 2001-0370            Impact factor:   7.271


  19 in total

1.  Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.

Authors:  Wenchao Tian; Xianxian Liu; Lulu Wang; Bufeng Zheng; Kun Jiang; Guoyong Fu; Wenyu Feng
Journal:  J Mol Model       Date:  2021-04-26       Impact factor: 1.810

2.  Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.

Authors:  Shibo Zhou; Bo Yang; Yufeng Xu; Aihua Gu; Juan Peng; Jinfeng Fu
Journal:  J Mol Model       Date:  2022-08-06       Impact factor: 2.172

3.  Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.

Authors:  Mingfei Ji; Zongtao Chai; Jie Chen; Gang Li; Qiang Li; Miao Li; Yelei Ding; Shaoyong Lu; Guanqun Ju; Jianquan Hou
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

4.  Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma.

Authors:  Cheng-Xiang Wang; Ting-Ting Wang; Kun-Dong Zhang; Ming-Yu Li; Qian-Cheng Shen; Shao-Yong Lu; Jian Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-03-29       Impact factor: 7.169

5.  How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.

Authors:  Shu Cao; Xu Jiang; Changbin Tan; Ming Fu; Wenqing Xiong; Dong Ji; Jun Lv
Journal:  J Mol Model       Date:  2021-11-02       Impact factor: 1.810

6.  Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.

Authors:  Shuai Liang; Qing Wang; Xuesen Qi; Yudi Liu; Guozhen Li; Shaoyong Lu; Linkai Mou; Xiangyu Chen
Journal:  Front Cell Dev Biol       Date:  2021-12-23

7.  Atomic-scale insights into allosteric inhibition and evolutional rescue mechanism of Streptococcus thermophilus Cas9 by the anti-CRISPR protein AcrIIA6.

Authors:  Xinyi Li; Chengxiang Wang; Ting Peng; Zongtao Chai; Duan Ni; Yaqin Liu; Jian Zhang; Ting Chen; Shaoyong Lu
Journal:  Comput Struct Biotechnol J       Date:  2021-11-16       Impact factor: 7.271

Review 8.  Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators.

Authors:  Yuran Qiu; Yuanhao Wang; Zongtao Chai; Duan Ni; Xinyi Li; Jun Pu; Jie Chen; Jian Zhang; Shaoyong Lu; Chuan Lv; Mingfei Ji
Journal:  Acta Pharm Sin B       Date:  2021-02-25       Impact factor: 11.413

9.  Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor.

Authors:  Ying Wang; Mingyu Li; Wenqi Liang; Xinchao Shi; Jigang Fan; Ren Kong; Yaqin Liu; Jian Zhang; Ting Chen; Shaoyong Lu
Journal:  Comput Struct Biotechnol J       Date:  2022-01-20       Impact factor: 7.271

10.  Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication.

Authors:  Yuran Qiu; Xiaolan Yin; Xinyi Li; Yuanhao Wang; Qiang Fu; Renhua Huang; Shaoyong Lu
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.